Oncolytics Biotech Stock News

Shares of Oncolytics Biotech Inc. (TSE:ONC) hit a new 52-week low during trading on Monday . The stock traded as low as C$1.85 and last traded at C$1.93, with a volume of 25835 shares trading hands. The stock had previously closed at C$1.94. The companys 50-day moving average is C$2.34 and its 200 day moving []

PALM BEACH, Fla. , Dec. 21, 2021 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - Breast cancer is cancer that develops in the breast tissue. Breast cancer signs include the formation of a lump in the breast and red patches on the skin. Obesity, lack of physical activity, excessive radiation exposure, and alcohol use are all risk factors for breast cancer. Breast cancer is more prevalent in developed countries than it is in developing countries. Post diagnosis, cancer therapy requires different procedures depending upon the form and severity of cancer. The cancer care market is increasing at a substantial pace due to the rise in the occurrence of cancer cases, growing knowledge among people about different stages, and availability of treatment of cancer. Breast cancer treatment relies on different factors, such as breast cancer origin, tumor size, and breast cancer phase, and cancer grade. Operations, radiation therapy, chemotherapy, hormone therapy, targeted therapy, and bone-led therapy are some of the most popular approaches used in the management of breast cancer.

Zacks Investment Research downgraded shares of Oncolytics Biotech (NASDAQ:ONCY) from a buy rating to a hold rating in a research note released on Wednesday, Zacks.com reports. According to Zacks, Oncolytics Biotech, Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human and companion pet cancers. The [] The post Oncolytics Biotech (NASDAQ:ONCY) Cut to Hold at Zacks Investment Research appeared first on ETF Daily News .

- Treatment with intravenous pelareorep plus azacitidine reduced tumor burden - Treatment with pelareorep and azacitidine dramatically upregulated multiple genes known to drive anti-cancer immune

Oncolytics Biotech (NASDAQ:ONCY) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research report issued on Wednesday, Zacks.com reports. According to Zacks, Oncolytics Biotech, Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human and companion pet cancers. The []

Oncolytics Biotech Inc. (TSE:ONC) shares reached a new 52-week low on Tuesday . The company traded as low as C$1.96 and last traded at C$1.97, with a volume of 62397 shares changing hands. The stock had previously closed at C$2.04. The company has a quick ratio of 17.84, a current ratio of 19.05 and a []

Oncolytics Biotech Inc. (NASDAQ:ONCY) price on Friday, December 10, fall -0.61% below its previous days close as a downside momentum from buyers pushed the stocks value to $1.63. A look at the stocks price movement, the close in the last trading session was $1.64, moving within a range at $1.61 and $1.6911. The beta value Oncolytics Biotech Inc.: When The Timing Is Right, Sit Tight Read More »

PALM BEACH, Fla. , Dec. 10, 2021 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - Ongoing advancements in cancer research continue to lead to the introduction of newer and better treatment options including drug therapies. The provision of newer drugs and treatments is expected to improve the diagnostic and treatment rate for triple-negative breast cancer . Some of the recent clinical efforts are being targeted at the molecular level characterization of triple-negative breast cancer across emerging therapeutic targets such as epigenetic proteins, PARP1, androgen receptors, receptor and non-receptor tyrosine kinases, and immune checkpoints. These initiatives are anticipated to boost revenue growth of the triple-negative breast cancer treatment market. In a new research study, Persistence Market Research estimates the global triple-negative breast cancer treatment market revenue to cross US$ 720 Mn by 2026 from an estimated valuation of just under US$ 505 Mn in 2018. This is indicative of a CAGR of 4.7% during the period 2018 to 2026.

- No safety concerns have been noted in any trial participants - Trial builds on prior clinical data demonstrating pelareorep''s ability to reverse immunosuppressive tumor microenvironments and upr

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Committee Votes Against Recommending Approval Of Kidney Disease Drug Reata Pharmaceuticals, Inc.

VANCOUVER, BC , Dec. 8, 2021 /PRNewswire/ -- USA News Group - Growing at a healthy CAGR of 14.1%, the Cancer Immunotherapy Market is being projected to hit nearly $310 billion by 2030, according to Allied Analytics . Over the past decade, cancer drug revenues increased 70%, according to a retrospective analysis . Last December, biotechs working on breast cancer treatments saw their shares soar . This year has continued that momentum, with multiple biotech companies driving progress in the fight against cancer, including from Oncolytics Biotech Inc. (NASDAQ: ONCY ) (TSX: ONC ), Incyte Corporation (NASDAQ: INCY ), BriaCell Therapeutics Corp. (NASDAQ: BCTX ), Gilead Sciences, Inc. (NASDAQ: GILD ), and Eli Lilly and Company (NYSE: LLY ). Coming up between December 11-14, 2021 , Oncolytics Biotech Inc. (NASDAQ: ONCY ) (TSX: ONC ) will give an update at the upcoming 63 rd American Society of Hematology Annual Meeting and Exposition (ASH 2021) on its Phase II Triple-Negative Breast Cancer Trial—known as the IRENE study, which is evaluating the company''s flagship product pelareorep, an immunotherapeutic agent that turns "cold" tumors "hot", in combination with the anti-PD-1 checkpoint inhibitor, retifanlimab, from Incyte Corporation (NASDAQ: INCY ).

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative development. The sector r

Oncolytics Biotech (ONCY) has been struggling lately, but the selling pressure may be coming to an end soon.

Oncolytics Biotech (ONCY) has been struggling lately, but the selling pressure may be coming to an end soon.